Surveillance for Babesiosis —

United States, 2018

Annual Summary

Acknowledgments

The findings in this U.S. surveillance summary were based, in part, on contributions by state and local health departments.

Suggested citation

Centers for Disease Control and Prevention (CDC). Surveillance for babesiosis — United States, 2018 Annual Summary. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2020.

Data current as of:

April 22, 2019 Additional data, updates, or corrections received after that date are not reflected in this summary.

Summary compiled by: Megan Swanson and Elizabeth B. Gray

Centers for Disease Control and Prevention Division of Parasitic Diseases and Malaria 1600 Clifton Road, Mailstop H24-3 Atlanta, GA 30329-4027 Telephone: 404-718-4745 E-mail: <u>parasites@cdc.gov</u> Web: <u>http://www.cdc.gov/parasites/babesiosis/data-statistics/</u>

Contents

Main Findings for 2018
Background
Babesiosis4
Surveillance4
Babesiosis national surveillance case definition (Table 1)6
2018 babesiosis surveillance summary
Surveillance data, 2011–2018
Table 2. Number and incidence of reported cases of babesiosis, by state and year, 2011–20189
Figure 1. Number of reported cases of babesiosis, by year, 2011–2018
Figure 2. Number of reported cases of babesiosis, by county of residence — 37 states, 2018
Figure 3. Number of reported cases of babesiosis, by age group and year, 2011–2018
Figure 4. Number of reported cases of babesiosis, by month of symptom onset and year, 2011–201814
References
Appendix

Main Findings for 2018

- For 2018, CDC was notified of a total of 2,161 U.S. cases of babesiosis, a 9% decrease from the total of 2,358 cases for 2017.
- Babesiosis was a reportable disease in 40 states and the District of Columbia (DC) in 2018 (compared with 37 states in 2017); 28 (70%) of the 40 states notified CDC of at least 1 case.
- Most of the reported cases (86%; n = 1,858/2,161) were in residents of 7 states where tickborne transmission of *Babesia* parasites is well established (the Northeast and upper Midwest: Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin)

Background

Babesiosis

Babesiosis is caused by protozoan parasites of the genus *Babesia*, which infect red blood cells. *Babesia* parasites are usually transmitted to humans by tick bites but can also be transmitted by blood transfusion or congenitally (mother to child) (1–3).

Most human cases of *Babesia* infection in the United States are caused by the parasite *Babesia microti*. Occasional U.S. cases caused by other species (types) of *Babesia* have been found (4, 5). *Babesia microti* is most commonly spread by *Ixodes scapularis* ticks (also called blacklegged ticks or deer ticks) primarily in the Northeast and upper Midwest, especially in parts of New England, New York State, New Jersey, Wisconsin, and Minnesota (1, 6–8). Babesiosis is spread by young nymph ticks which are often found in woods, brushy areas, or grass during warmer months (spring and summer). The ticks are very small (about the size of a poppy seed); because of their small size infected people might not remember having a tick bite.

Many people who are infected with *Babesia microti* are asymptomatic. Some people develop flu-like symptoms, such as fever, chills, sweats, headache, body aches, loss of appetite, nausea, or fatigue. Babesiosis can also cause severe complications such as hemolytic anemia, a very low platelet count (thrombocytopenia), malfunction of the vital organs (acute respiratory failure, congestive heart failure, and renal failure) and death (7).

Babesiosis can be a severe, life-threatening disease (1, 7), particularly in people who:

- do not have a spleen;
- have a weak immune system for other reasons (such as cancer, lymphoma, or AIDS);
- have other serious health conditions (such as liver or kidney disease); or
- are elderly.

Surveillance

CDC has conducted surveillance for babesiosis in the United States since January 2011, when babesiosis became a nationally notifiable condition. The babesiosis case definition used for surveillance purposes is available online (<u>http://wwwn.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/</u>) and is summarized in **Table 1**. Health departments in states where babesiosis is reportable notify CDC of cases that meet the definition via the **National Notifiable Diseases Surveillance System (NNDSS)**.

Health departments submit additional information about reported cases using the CDC Case Report Form (CRF) **Babesiosis CRF** ¹ [PDF, 2 pages, 650 KB]; data are requested about risk factors for infection, clinical manifestations, and laboratory results. Of note, for some cases, requested data elements may be incomplete or missing. For example, data regarding clinical manifestations are collected as distinct questions, resulting in differences in the denominator across each sign/symptom. For more information, visit

babesiosis surveillance and case reporting. Health care providers, laboratories, and the general public should contact their state health department for information about reporting cases of babesiosis.

The number of states in which babesiosis is a reportable condition may change from year to year as additional states begin conducting surveillance. Cases are reported by state and county of residence, which is not necessarily where the exposure occurred. Changes in the number of reported cases do not necessarily represent true changes in disease incidence; ascertainment, reporting, and investigation of cases are subject to clinician awareness and public health agency resources, which may vary from year to year in and among states.

This summary focuses on babesiosis cases reported for surveillance year 2018; some data from previous years (2011–2017) are included to show differences from year to year. Babesiosis surveillance data also are presented in CDC's <u>Morbidity and Mortality Weekly Report (MMWR)</u> weekly and annual summaries of nationally notifiable diseases. In addition, national surveillance data for 2011 and a 5-year summary (2011–2015) were published previously (8, 9). Because of differences in the timeline for finalizing data in the annual surveillance datasets, data provided in this summary may differ slightly from those previously published. Of note, the year in which a case is counted in national surveillance summaries is assigned by the health department and might reflect the year of symptom onset, diagnosis, or of reporting to or by the health department.

Clinical evidence	Objective									
	One or more of the following: fever, anemia, or thrombocytopenia.									
	Subjective									
	One or more of the following: chills, sweats, headache, myalgia, or arthralgia.									
Epidemiologic	For the purposes of surveillance, epidemiologic linkage between a transfusion									
evidence for	recipient and a blood donor is demonstrated if all of the following criteria are met:									
transfusion										
transmission	In the transfusion recipient									
	Received one or more red blood cell (RBC) or platelet transfusions within 1 year before the collection date of a specimen with laboratory evidence of <i>Babesia</i> infection; and									
	At least one of these transfused blood components was donated by the donor described below; and									
	Transfusion-associated infection is considered at least as plausible as tickborne transmission; and									
	In the blood donor									
	Donated at least one of the RBC or platelet components that was transfused into the above recipient; and									
	The plausibility that this blood component was the source of infection in the recipient is considered equal to or greater than that of blood from other involved donors. (More than one plausible donor can be linked to the same recipient.)									
Laboratory	Laboratory confirmatory									
criteria for diagnosis	Identification of intraerythrocytic <i>Babesia</i> organisms by light microscopy in a Giemsa, Wright, or Wright-Giemsa–stained blood smear; or									
	Detection of <i>Babesia microti</i> DNA in a whole blood specimen by polymerase chain reaction (PCR); or									
	Detection of <i>Babesia</i> spp. genomic sequences in a whole blood specimen by nucleic acid amplification; or									
	Isolation of <i>Babesia</i> organisms from a whole blood specimen by animal inoculation.									
	Laboratory supportive									
	Demonstration of a Babesia microti indirect fluorescent antibody (IFA) total									
	immunoglobulin (Ig) or IgG antibody titer of ≥1:256 (or ≥1:64 in epidemiologically linked blood donors or recipients); or									
	Demonstration of a <i>Babesia microti</i> immunoblot IgG positive result; or									
	Demonstration of a <i>Babesia divergens</i> IFA total Ig or IgG antibody titer of ≥1:256; or									
	Demonstration of a <i>Babesia duncani</i> IFA total Ig or IgG antibody titer of \geq 1:512.									

Table 1. National surveillance case definition for babesiosis*

Case classification	on
Confirmed	A case that has confirmatory laboratory results and meets at least one of the objective or subjective clinical evidence criteria, regardless of the mode of transmission (can include clinically manifest cases in transfusion recipients or blood donors).
Probable	 A case that has supportive laboratory results and meets at least one of the objective clinical evidence criteria (subjective criteria alone are not sufficient); or A case that is in a blood donor or recipient epidemiologically linked to a confirmed or probable babesiosis case (as defined above) and Has confirmatory laboratory evidence but does not meet any objective or subjective clinical evidence criteria; or Has supportive laboratory evidence and might or might not meet any subjective clinical evidence criteria but does not meet any objective clinical evidence criteria is or meet any objective clinical evidence criteria.

* Available at <u>http://wwwn.cdc.gov/nndss/conditions/babesiosis/case-definition/2011/</u>

2018 babesiosis surveillance summary

In 2018, babesiosis was a reportable condition in 40 states (compared with 37 states in 2017). CDC was notified of a total of 2,161 cases of babesiosis by 28 of the 40 states (70%) (**Table 2**), a 9% decrease from the total of 2,358 cases for 2017 (**Figure 1**). For 2018, 86% (n = 1,858/2,161) of the reported cases were residents of 7 states (Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin). Tickborne transmission of *Babesia* parasites is well established in parts of these states. Differences within and among states in the distributions of reported cases by place of residence are evident in the county-level maps for 2018 (**Figure 2**) and the 7 prior years (2011–2017) in which national surveillance was conducted (**Appendix**). Among the 213 counties with at least 1 reported cases of babesiosis for 2018, 149 counties (70%) reported 1–5 cases, 13 counties (6%) reported 6–10 cases, 23 counties (11%) reported 11–20 cases, and 29 (14%) had >20 reported cases. The 29 counties with >20 cases reported were in New York (n=9), Massachusetts (n=7), Connecticut (n=5), New Jersey (n=4), Rhode Island (n=3), and Maine (n=1). Many cases in states without well-established local transmission of babesiosis had documented travel to areas with established local transmission. Changes in the number of states conducting surveillance for babesiosis had minimal impact on the fluctuations in the yearly totals of cases; the three states that began surveillance for babesiosis in 2018—Arizona, Georgia and Kansas—reported no cases.

Virginia reported their first cases of babesiosis in 2018, with 5 cases. Of these cases 3 were hospitalized, 2 died. Four of 5 reported travel to areas with documented local transmission of babesiosis.

For 2018, the majority of cases in the United States were older, with a median age of 63 years old (range: <l-101 years; n = 2,157). The age distributions for 2018 and the 7 previous years were similar (**Figure 3**), with the largest number of cases reported in persons aged 60–69 years. Similar to the data for previous years, for 2018 among the 2,158 case-patients for whom data on sex were available, 65% (n = 1,401) were male and 35% (n=757) were female.

A majority of case-patients reported getting sick during the spring or summer months, which is consistent with tick activity. Data on month of symptom onset were available 69% of case-patients (n = 1,497/2,161). The proportion of case-patients with reported symptom onset during June-August has remained consistent from year to year (**Figure 4**).

For 2018, among the case-patients for whom data were available, fever was the most frequently reported clinical manifestation (79%; n = 1,488/1,894 patients), followed by myalgia (68%; n = 1,140/1,666), chills (65%; n = 1,046/1,619), thrombocytopenia (64%; n = 748/1,174), anemia (61%; n = 734/1203), and headache (60%; n = 971/1,629); proportions are similar to previous years.

For 2018, 633 (45%) people were hospitalized for at least 1 day; hospitalization data were available for 1,488 case-patients. These data are consistent with previous years; overall for 2011–2018, data were available for 11,112 case-patients (83% of the total of 13,369), 5,110 (46%) of whom had reportedly been hospitalized for at least 1 day. In 2018, 10 cases died with 4 deaths occurring in Massachusetts, 3 in New Jersey, 2 in Virginia, and 1 in Wisconsin; with an overall death rate of 0.46%

Babesiosis is primarily transmitted via tick bites but can also be transmitted through blood transfusions, transplants, and from mother to child (congenitally). In 2018, of the 865 case-patients for whom data were available, 371 (43%) recalled having a tick bite in the 8 weeks before symptom onset. There were 2 cases of babesiosis in blood recipients which were classified by the reporting state as transfusion-associated.

Table 2. Number and incidence of reported cases of babesiosis, by state and year, 2011–2018*	
Tuble Intumber and meraence of reported cases of bubesions, by state and year, is in iteration	

	2011 2		2	2012 2013		2014		2015		2016		2017		2018		
State [†]	No.	Rate [‡]	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate
Alabama	1	< 0.1	0	0	0	0	1	< 0.1	2	<0.1	0	0	1	<0.1	0	0
Alaska§	_	—	_	_			_	_	—		—	_			_	
Arizona	_	_	—	_	—	_	_	—	—	_	—	_	—	_	0	0
Arkansas	—	—	—	—	—	—	—	—	0	0	1	<0.1	0	0	2	<0.1
California	1	< 0.1	4	< 0.1	3	<0.1	3	< 0.1	5	<0.1	3	<0.1	4	<0.1	6	<0.1
Colorado§	—	—	—	—			—	—	—	—	—		—	—	—	—
Connecticut	74	2.1	123	3.4	268	7.5	205	5.7	328	9.1	322	9	309	8.6	248	6.9
Delaware	1	0.1	0	0	2	0.2	1	0.1	1	0.1	2	0.2	4	0.4	3	0.3
District of Columbia	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2	0.3
Florida	—	—	—	—	—	—	—	—	—	—	—	—	9	<0.1	19	<0.1
Georgia	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0
Hawaii§	—	—	—	—	—	—	—	—	—		—	—	—	—	—	—
Idaho [§]	—	—	—	—			—	—	—		—		—	—	—	—
Illinois	—	—	—	—	—	—	1	<0.1	3	<0.1	2	<0.1	0	0	1	<0.1
Indiana	0	0	1	< 0.1	1	<0.1	0	0	0	0	0	0	1	<0.1	1	<0.1
Iowa	—	—	—	_	—	_	—	—	—	—	—	—	2	0.1	0	
Kansas	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0
Kentucky	—	—	—	—	—	—	—	—	0	0	0	0	0	0	0	0
Louisiana	—	—	—	—	2	<0.1	0	0	1	<0.1	0	0	1	<0.1	1	<0.1
Maine	9	0.7	10	0.8	36	2.7	42	3.2	55	4.1	82	6.2	118	8.8	101	7.5
Maryland	4	0.1	3	0.1	9	0.2	2	<0.1	4	0.1	6	0.1	5	<0.1	7	0.1
Massachusetts	208	3.1	261	3.9	417	6.2	535	7.9	444	6.5	517	7.6	591	8.6	527	7.6
Michigan	0	0	0	0	2	<0.1	2	<0.1	3	<0.1	2	<0.1	3	<0.1	1	<0.1
Minnesota	73	1.4	41	0.8	64	1.2	49	0.9	45	0.8	50	0.9	60	1.1	49	0.9
Mississippi§	—	—	—	—	—		—	—	—	—	—	—	—	—	—	—
Missouri	—	—	—	—	—			—		—	1	< 0.1	0	0	0	0
Montana	—	—	—	—	—		0	0	0	0	1	0.1	0	0	0	0
Nebraska	0	0	1	0.1	1	0.1	0	0	0	0	1	0.1	0	0	0	0
Nevada§	—	—	—	—		—	—	—	—	—	—	—	—	—	—	—

New Hampshire	13	1	19	1.4	22	1.7	42	3.2	53	4	13	1	78	5.8	37	2.7
New Jersey	166	1.9	92	1	171	1.9	159	1.8	281	3.1	174	1.9	193	2.1	247	2.8
New Mexico [§]	—		—	_	_	_	—	_	—	—	—	—	—	_	_	_
New York	418	2.1	253	1.3	534	2.7	471	2.4	581	2.9	430	2.2	696	3.5	641	3.3
North Carolina§	—		—	—	—	—	—	—	—	—	—	—	—	—		—
North Dakota	1	0.1	0	0	1	0.1	0	0	3	0.4	1	0.1	0	0	1	0.1
Ohio	—		—	—	—	_	1	< 0.1	2	< 0.1	—	_	1	< 0.1	4	<0.1
Oklahoma§	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oregon	1	<0.1	0	0	0	0	1	< 0.1	2	< 0.1	2	< 0.1	5	0.1	2	<0.1
Pennsylvania§	—		—	—	—	—	—	—	—	—	—		—	—		—
Rhode Island	73	6.9	56	5.3	142	13.5	172	16.3	190	18	155	14.7	161	15.2	165	15.6
South Carolina	—		—	—	1	< 0.1	3	0.1	2	< 0.1	2	< 0.1	2	< 0.1	1	<0.1
South Dakota	—		—	—	1	0.1	1	0.1	0	0	0	0	0	0	0	0
Tennessee	1	<0.1	0	0	0	0	0	0	1	<0.1	1	< 0.1	1	< 0.1	1	<0.1
Texas	—		—	—	1	< 0.1	1	< 0.1	1	<0.1	1	< 0.1	0	0	2	<0.1
Utah	—		—	—	—	—	0	0	0	0	0	0	1	< 0.1	1	<0.1
Vermont	2	0.3	2	0.3	6	1	3	0.5	9	1.4	15	2.4	22	3.5	21	3.4
Virginia	—	—	—	—	—	_	—	—	—	_	—	_	0	0	5	<0.1
Washington	0	0	0	0	1	<0.1	4	0.1	2	<0.1	0	0	1	< 0.1	0	0
West Virginia	—		—	—	0	0	0	0	0	0	0	0	1	0.1	1	<0.1
Wisconsin	80	1.4	45	0.8	76	1.3	43	0.7	56	1	68	1.2	88	1.5	64	1.1
Wyoming	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total	1,126	0.8	911	0.6	1,761	1	1,742	0.8	2,074	0.9	1,909	0.8	2,358	0.9	2,161	0.77

* Year as reported by the health department [†] Cases were reported by state of residence, which was not necessarily the state of exposure.

* Rate per 100,000 population (10)

 [§] Babesiosis is not a reportable condition by law in these states
 [¶] The denominators for calculations of total incidence rates included only the populations of states in which babesiosis was a reportable condition during the pertinent year




Figure 1. Number* of reported cases of babesiosis, by year, $2011-2018^{\dagger}$

* A total of 14,042 cases of babesiosis were reported (2011, n = 1,126; 2012, n = 911; 2013, n = 1,761; 2014, n = 1,742; 2015, n = 2,074; 2016, n = 1,909; 2017, n = 2,358; 2018, n=2,161). † Year as reported by the health department.




Figure 2. Number* of reported cases of babesiosis, by county of residence — 40 states, 2018[†]

* N = 2,144; county of residence was known for all but 17 (1%) of the 2,161 total case-patients. See the Appendix for the maps for surveillance years 2011-2017.

[†] Year as reported by the health department.




Figure 3. Number of reported cases of babesiosis, by age group* and year, 2011-2018⁺

* Data on age were available for most case-patients (2011, n = 1,041/1,126; 2012, n = 785/911; 2013, n = 1,523/1,761; 2014, n = 1,740/1,742; 2015, n = 2,074/2,074; 2016, n = 1,902/1,909; 2017, n = 2,347/2,358; 2018, n=2,157/2,161). † Year as reported by the health department.




Figure 4. Number of reported cases of babesiosis, by month of symptom onset* and year, 2011–2018[†]


* Data on month of symptom onset were available for most case-patients (2011, n = 932/1,126; 2012, n = 644/911; 2013, n = 1,352/1,761; 2014, n = 1,340/1,742; 2015, n = 1,665/2,074; 2016, n = 1,483/1,909; 2017, n = 1,772/2,358; 2018, n=1,497/2161).

[†] Year as reported by the health department.

References


- 1. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011;155:509–19.
- 2. Joseph JT, Purtill K, Wong SJ, et al. Vertical transmission of *Babesia microti*, United States. Emerg Infect Dis 2012;18:1318–21.
- 3. Fox LM, Wingerter S, Ahmed A, et al. Neonatal babesiosis: case report and review of the literature. Pediatr Infect Dis J 2006;25:169–73.
- Conrad PA, Kjemtrup AM, Carreno RA, et al. Description of *Babesia duncani* n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol 2006;36:779– 89.
- 5. Herwaldt BL, de Bruyn G, Pieniazek NJ, et al. *Babesia divergens*–like infection, Washington State. Emerg Infect Dis 2004;10:622–9.
- 6. Herwaldt BL, McGovern PC, Gerwel MP, Easton RM, MacGregor RR. Endemic babesiosis in another eastern state: New Jersey. Emerg Infect Dis 2003;9:184–8.
- 7. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089–134. Erratum in: Clin Infect Dis 2007;45:941.
- 8. Centers for Disease Control and Prevention. Babesiosis surveillance 18 states, 2011. Morb Mortal Wkly Rep 2012;61:505–9.
- 9. Gray EB, Herwaldt BL. Babesiosis surveillance United States, 2011–2015. MMWR Surveill Summ 2019;68(No. SS-6):1–11. DOI: <u>http://dx.doi.org/10.15585/mmwr.ss6806a1</u>
- 10. US Census Bureau. Annual estimates of the resident population: April 1, 2010 to July 1, 2018. Washington, DC: US Census Bureau; 2018. <u>https://www.census.gov/newsroom/press-kits/2018/pop-estimates-national-state.html</u>. Accessed on April 1 2020.

Appendix. Maps for surveillance years 2011–2017




2011: Number* of reported cases of babesiosis, by county of residence - 22 states[†]

* N = 1,117; county of residence was known for all but 9 (1%) of the 1,126 total case-patients. † Year as reported by the health department.




2012: Number* of reported cases of babesiosis, by county of residence – 22 states[†]

* N = 904; county of residence was known for all but 7 (1%) of the 911 total case-patients. † Year as reported by the health department.




2013: Number* of reported cases of babesiosis, by county of residence – 27 states[†]

* N = 1,749; county of residence was known for all but 12 (1%) of the 1,761 total case-patients. [†] Year as reported by the health department.




2014: Number* of reported cases of babesiosis, by county of residence — 31 states[†]

* N = 1,731; county of residence was known for all but 13 (1%) of the 1,742 total case-patients. † Year as reported by the health department.




2015: Number* of reported cases of babesiosis, by county of residence - 33 statest

* N = 2,070; county of residence was known for all but 4 (<1%) of the 2,074 total case-patients. † Year as reported by the health department.



2016: Number* of reported cases of babesiosis, by county of residence — 35 states[†]

* N = 1,889; county of residence was known for all but 20 (1%) of the 1,909 total case-patients. † Year as reported by the health department.



2017: Number* of reported cases of babesiosis, by county of residence — 37 states[†]

* N = 2,324; county of residence was known for all but 34 (1%) of the 2,358 total case-patients $^{+}$ Year as reported by the health department.